On phase II , trial patients with p16-negative hypoxic tumours had worse loco-regional control with cisplatin and 5FU compared with tirapazamine and cisplatin ( P < 0.001 ) and worse failure-free survival ( hazard ratio = 5.18 ; 95 % confidence interval , 1.98-13 .55 ; P = 0.001 ) .